Drug Trial Radar · NCT07851649
A Study to Assess the Bioavailability and Adhesion of Estradiol/Levonorgestrel TDS in Healthy Post-Menopausal Female Participants
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
68
Actual
Start
Jul 1, 2026
Primary completion
Sep 29, 2026
Study completion Sep 29, 2026
Sponsor
- Lead sponsor
- Corium Innovations, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 1, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 45 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the bioequivalence and adhesion performance of a test estradiol/levonorgestrel transdermal delivery system (TDS) with the reference product, Climara Pro® (estradiol/levonorgestrel transdermal system), following a single 7-day application in healthy postmenopausal female participants. The study will also evaluate the safety and tolerability of the test and reference patches.
Conditions
- Healthy Female Participants
- Postmenopause
Interventions
Test Estradiol/Levonorgestrel Transdermal Delivery SystemDrug
Investigational estradiol/levonorgestrel transdermal delivery system containing estradiol 0.045 mg/day and levonorgestrel 0.015 mg/day. A single patch is applied to the upper quadrant of the buttock and worn continuously for 168 hours (7 days).
Climara Pro® (Estradiol/Levonorgestrel Transdermal System)Drug
Reference-listed estradiol/levonorgestrel transdermal system (Climara Pro®) containing estradiol 0.045 mg/day and levonorgestrel 0.015 mg/day. A single patch is applied to the upper quadrant of the buttock and worn continuously for 168 hours (7 days).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Plasma Concentration (Cmax) of Baseline-Corrected EstradiolTime frame: Predose through 288 hours after patch application
- Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Baseline-Corrected EstradiolTime frame: Predose through 288 hours after patch application
- Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Baseline-Corrected EstradiolTime frame: Predose through 288 hours after patch application
- Maximum Plasma Concentration (Cmax) of LevonorgestrelTime frame: Predose through 288 hours after patch application
- Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of LevonorgestrelTime frame: Predose through 288 hours after patch application
- Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of LevonorgestrelTime frame: Predose through 288 hours after patch application
- Mean Adhesion Score (MAS)Time frame: Immediately after patch application through 168 hours after patch application
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Lambda Therapeutic Research Ltd.
Ahmedabad, Gujarat, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.